Leo Pharma gets green light from FDA for Adbry autoinjector

The US Food and Drug Administration (FDA) has approved an autoinjector for Leo Pharma’s Adbry for the treatment of adults with moderate to severe atopic dermatitis (AD). 
Photo: Leo Pharma / Pr
Photo: Leo Pharma / Pr

Leo Pharma has received FDA approval for a new 300 mg. single-dose autoinjector for Adbry for the treatment of moderate to severe atopic dermatitis in patients 12 years and older.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Photo: Mike Blake/Reuters/Ritzau Scanpix

    Gilead Sciences CMO to leave early 2025

    For subscribers

    Further reading